<https://rdf.molmedb.upol.cz/reference/ref3703> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM491568>;
	<http://purl.org/ontology/bibo/pmid> "32292557"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acsmedchemlett.9b00621"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>,
		<https://identifiers.org/molmedb/MM491549>,
		<https://identifiers.org/molmedb/MM491570>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Blomgren P, Chandrasekhar J, Di Paolo JA, Fung W, Geng G, Ip C, Jones R, Kropf JE, Lansdon EB, Lee S, Lo JR, Mitchell SA, Murray B, Pohlmeyer C, Schmitt A, Suekawa-Pirrone K, Wise S, Xiong JM, Xu J, Yu H, Zhao Z, Currie KS.: Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases. ACS Med Chem Lett, Volume 11 (4), 2020"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21>,
		<https://identifiers.org/molmedb/MM491545> .
<https://rdf.molmedb.upol.cz/interaction/int1025792> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3703> .
<https://rdf.molmedb.upol.cz/interaction/int1025822> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3703> .
<https://rdf.molmedb.upol.cz/interaction/int1025786> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3703> .
<https://rdf.molmedb.upol.cz/interaction/int1025819> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3703> .